Table 3.
Published details of HIP1-ALK-positive NSCLC patients treated with ALK-TKIs.
| Ref | Year | Variants | ALK-TKIs | Treatment | Response | |
|---|---|---|---|---|---|---|
| 1 | Fang, D.D. et al. [93] | 2014 | (H28:A20) | Not treated with ALK-TKIs | – | PDX is sensitive to crizotinib |
| 2 | Hong, M., et al. [20] | 2014 | (H21:A20) | Crizotinib | First line | PFS > 15 m |
| 3 | Ou, S.H., et al. [90] | 2014 | (H30:A20) | Crizotinib Alectinib |
First line Second line |
PD PFS > 12 m |
| 4 | Jang, J. S, et al. [92] | 2016 | (H19:A20) | Not treated with ALK-TKIs | – | Not reported |
| 5 | Couetoux, D. T. M, et al. [94] | 2019 | (H28:A20) | Crizotinib | First line | PR PFS:26.9 m |
| 6 | Tian, P, et al. [89] | 2020 | (H22:A21) | Crizotinib | First line | PR PFS: 7.0 m |
| 7 | Li, M, et al. [24] | 2021 | (H19:A20) | Crizotinib Alectinib |
First line Second line |
PD PFS > 9 m |
| 8 | Li Y, et al. [91] | 2022 | (H30:A20) | Alectinib | First line | PFS > 19 m |